ly3015014
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01426412)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3015014
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01890967 | Phase 2 | Jun 1, 2013 | Eli Lilly |
| NCT01671085 | Phase 1 | Aug 1, 2012 | Eli Lilly |
| NCT01618916 | Phase 1 | Jun 1, 2012 | Eli Lilly |
| NCT01426412 | Phase 1 | Sep 1, 2011 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2011 |
1 organizations
Page 1 / 1